Mark DePristo, former CEO of BigHat Biosciences, reveals why the best biotech innovation doesn't bolt on AI later but bakes it into research from day one. He shifts from scaling a clinical-stage antibody powerhouse to the nimble "zero-to-one" world of Ember AI Studios, where small teams leverage AI to solve overlooked deep-tech problems. Mark illustrates how embedding high-throughput experimental loops into design processes creates a rhythm that feels less like a lab experiment and more like a jazz band finding its collective, synchronized flow.


Rss
Podden och tillhörande omslagsbild på den här sidan tillhör Machines and Molecules. Innehållet i podden är skapat av Machines and Molecules och inte av, eller tillsammans med, Poddtoppen.